🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being viewed as a "huge turning point" in the effort against superbug strains of the infection, according to health experts.

A Global Health Concern

The sexually transmitted infection are on the rise globally, with data suggesting over 82 million new cases annually. Particularly high rates are seen in Africa and nations within the World Health Organization's designated area, which spans from Mongolia and China to New Zealand. In England, cases have reached a all-time high, while rates across Europe in 2023 were triple the level compared to those in 2014.

“The approval of novel therapies for gonorrhoea is an important and timely development in the context of rising global incidence, the spread of superbugs and the highly restricted therapeutic options presently on offer.”

Public health authorities are increasingly worried about the surge in antibiotic-resistant strains. The WHO has designated it as a "critical concern". Recent surveillance showed that the effectiveness of key first-line drugs like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Recent Treatment Options Gain Authorization

One new antibiotic, also known as a brand name, was approved by the American regulatory agency in recent days for use against gonorrhoea. This infection can lead to significant complications, including the inability to conceive. Scientists hope that focused deployment of this new drug will help hinder the spread of drug resistance.

Another new antibiotic, developed by the drugmaker GSK, also received approval in close succession. This medication, which is employed against urinary tract infections, was shown in trials to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Unique Development Model

This new treatment emerged from a unique collaborative effort for drug creation. The non-profit organisation GARDP partnered with the drug firm its industry partner to develop it.

“This milestone signifies a huge turning point in the treatment of highly resistant gonorrhoea, which previously has been evolving faster than our drug pipeline.”

Clinical Trial Outcomes and Global Access

As per data detailed in a major medical journal, the new drug eradicated more than 90% of genital gonorrhoea infections. This establishes an equal footing with the current standard treatment, which uses a dual-drug approach. The study involved hundreds of volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its unique model, GARDP has the ability to make available and distribute the drug in numerous low-income and middle-income countries.

Clinicians on the front lines have shared positive views. Access to a single-dose, oral treatment of this kind is hailed as a "critical tool" for gonorrhoea control. This is considered essential to reduce the burden of the disease for individuals and to prevent the spread of extremely resistant gonorrhoea around the world.